Back to Search Results

Montelukast and Coronavirus Disease 2019: A Scoping Review.

Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran AND Alborz Office of Universal Scientific Education and Research Network (USERN), Alborz University of Medical Sciences, Karaj, Iran. marzieh.tavakol@yahoo.com. Department of Allergy and Clinical Immunology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. marziyeh.tavakol@gmail.com. Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran. marziyeh.tavakol@gmail.com. Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran. marzieh.tavakol@yahoo.com. Social Determinants of Health Research Center, Alborz University of Medical Sciences, Karaj, Iran. marziyeh.tavakol@gmail.com.

Iranian journal of allergy, asthma, and immunology. 2021;(4):384-393
Full text from:

Other resources

Abstract

Coronavirus disease 2019 (COVID-19) is an emerging worldwide issue, that has affected a large number of people around the world. So far, many studies have aimed to develop a therapeutic approach against COVID-19. Montelukast (MK) is a safe asthma controller drug, which is considered as a potential antiviral drug for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This review has a systematic approach to investigate the reports on the use of MK as a part of treatment or a prophylactic agent in COVID-19. The search was conducted in PubMed, Web of Science, and Scopus databases and yielded 35 studies containing the influence of MK on SARS-CoV-2. Ultimately, MK appears to be worth being used as an adjuvant therapeutic and prophylactic drug against SARS-CoV-2. Nevertheless, more clinical trials are required to accurately investigate its effectiveness.

Methodological quality

Publication Type : Review

Metadata